Search

According to the Pan American Health Organization, noncommunicable diseases, including cancer, are the leading causes of preventable and premature death in the Americas. Governments and health care systems in Latin America face numerous challenges as a result of increasing morbidity and mortality from cancer. Multiple international organizations have recognized the need for collaborative action on and technical support for cancer research and control in Latin America. The Center for Global Health at the US National Cancer Institute (NCI-CGH) is one entity among many that are working in the region and has sought to develop a strategy for working in Latin America that draws on and expands the collaborative potential of engaged, skilled, and diverse partners. NCI-CGH has worked toward developing and implementing initiatives in collaboration with global partners that share the common objectives of building a global cancer research community and translating research results into evidence-informed policy and practice. Both objectives are complementary and synergistic and are additionally supported by an overarching strategic framework that is focused on partnerships and science diplomacy. This work highlights the overall strategy for NCI-CGH engagement in Latin America through partnerships and diplomacy, and highlights selected collaborative efforts that are aimed at improving cancer outcomes in the region.

The steady increase in cancer incidence and mortality in the Asia-Pacific presents a growing challenge to countries in the region. National cancer control planning provides key strategies for countries to decrease their cancer burden and address risk factors in the context of their populations and health systems. Evidence-guided approaches allow countries to target resources towards highly-needed and effective cancer programs, while partnerships can serve to diversify sources of support, increase coverage and sustain services. Many countries struggle to develop and implement national cancer control plans (NCCPs) due to barriers in coordinating diverse stakeholders, limited funding and absence of evidence to guide program and health infrastructure improvements. The Cancer Control Leadership Forum (CCLF) program aims to address critical hurdles in cancer control planning by: (1) convening cancer control leaders from diverse sectors; (2) raising awareness and capacity of participating country representatives to develop and implement NCCPs; (3) facilitating development of country action-plans; and (4) providing technical assistance. Two years after participating in their first CCLF, eight countries from Southeast Asia and the Pacific, represented by multiple cancer control leaders from each country, participated in an Asia-Pacific Leadership Forum Phase II (APLF2) in 2016. The APLF2 facilitated valuable experience-exchange amongst regional and international experts, and explored areas of common interest, including: improving cancer registries, strengthening training, coordinating stakeholders, maximizing resources and overcoming implementation challenges. These priorities guide on-going cancer control efforts and serve to inform the international community of trends, needs and challenges in cancer control in Southeast Asia and the Pacific.

As the burden of non-communicable diseases such as cancer continues to rise in low- and middle-income countries (LMICs), it is essential to identify and invest in promising solutions for cancer control and treatment. Point-of-care technologies (POCTs) have played critical roles in curbing infectious disease epidemics in both high- and low-income settings, and their successes can serve as a model for transforming cancer care in LMICs, where access to traditional clinical resources is often limited. The versatility, cost-effectiveness, and simplicity of POCTs warrant attention for their potential to revolutionize cancer detection, diagnosis, and treatment. This paper reviews the landscape of affordable POCTs for cancer care in LMICs with a focus on imaging tools, in vitro diagnostics, and treatment technologies and aspires to encourage innovation and further investment in this space., This review explores the current landscape of point-of care (POC) tools available for cancer detection, diagnosis, and treatment in resource-limited settings. With a concerted effort to support international collaborations in technology development, fund promising POC technology concepts for translation in low-resource settings, and train the next generation of scientists in resource-appropriate design, the engineering research community can be a vital part of delivering quality cancer care to all patients.

Point-of-care (POC) technologies have proved valuable in cancer detection, diagnosis, monitoring, and treatment in the developed world, and have shown promise in low-and-middle-income countries (LMIC) as well. Despite this promise, the unique design constraints presented in low-resource settings, coupled with the variety of country-specific regulatory and institutional dynamics, have made it difficult for investigators to translate successful POC cancer interventions to the LMIC markets. In response to this need, the National Cancer Institute has partnered with the National Institute of Biomedical Imaging and Bioengineering to create the National Institutes of Health Affordable Cancer Technologies (ACTs) program. This program seeks to simplify the pathway to market by funding multidisciplinary investigative teams to adapt and validate the existing technologies for cancer detection, diagnosis, and treatment in LMIC settings. The various projects under ACTs range from microfluidic cancer diagnostic tools to novel treatment devices, each geared for successful clinical adaptation to LMIC settings. Via progression through this program, each POC innovation will be uniquely leveraged for successful clinical translation to LMICs in a way not before seen in this arena., This paper describes the purpose, formation, and early results of the National Institutes of Health Affordable Cancer Technologies Program, which aims to improve access to resource-appropriate technologies for cancer detection, diagnosis, monitoring and treatment in low- and middle-income countries.

9 Cancer kills more people worldwide than HIV/AIDS, tuberculosis, and malaria combined, and lowand middle-incomecountries (LMICs) bear themajority of this burden.While success indetection, diagnosis, and treatment hasbeen reported in LMICs through theuse of low-cost, point-of-care (POC) technologies, this areahasbeen largely overlookedby themedical device industry and venture capital communities, as low-cost solutions offer less financial incentive for investment. The program presented here aims to simplify the pathway tomarket by funding investigation teams to adapt and validate existing technologies in low-resource settings. This program specifically supports the translation of these technologies, prioritizing patient outcomes in a manner not typically seen. This program, currently in its second year, will soon support 15 technologies for cancer detection, diagnosis, and treatment (e.g., in vitro assays, imaging devices, ablation devices). It is anticipated that by year seven of the program, at least nine projects will have progressed through optimization, clinical validation, and business planning for dissemination and commercialization. Each project consists of an adaptation phase (two years: $500k total costs/year) and validation phase (three years: $1M total costs/year). Projects are selected through the National Institutes of Health peer review process by a special emphasis panel briefed on the goals of the program. Projects are competitively vetted for Phase II funding based on completion of Phase I milestones. All teams contain expertise in engineering, oncology, and business/manufacturing, uniquely leveraging their devices for success in translation. The seven preliminarily funded projects are making strides in optimization, and the projects range from anLED-based photodynamic therapy device for oral cancer to POC tests for Hepatitis C viral antigen level and viral load detection. This program is funded by theNational Cancer Institute and theNational Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors. Michael Gwede,Pushpa Tandon,Miguel Ossandon,Houston Baker,Rao Divi, Lokesh Agrawal, andPaul C. Pearlman, National Cancer Institute, National Institute of Health, Department of Health and Human Services, United States of America; and Vinay Pai and Tiffani Lash,National Institute ofBiomedical ImagingandBioengineering,National Institute ofHealth,Department ofHealthand Human Services, United States of America Corresponding author:Michael Gwede,National Cancer Institute, 9609Medical CenterDr, Rockville,MD20850; 240-276-7634; Michael.gwede@nih.gov DOI: 10.1200/JGO.2016.004499 Michael Gwede Pushpa Tandon Vinay Pai Miguel Ossandon Houston Baker Tiffani Lash Rao Divi Lokesh Agrawal Paul C. Pearlman 17s jgo.ascopubs.org JGO – Journal of Global Oncology © 2016 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License

Cancer kills more people worldwide than HIV/AIDS, tuberculosis and malaria combined, and low-and-middle income countries (LMICs) bear the majority of this burden. Success in detection, diagnosis and treatment has been reported in LMICs through the use of low-cost point-of-care (POC) technologies, and the program presented offers a unique pathway to this POC market by funding multidisciplinary investigative teams to adapt and clinically validate existing technologies for cancer detection, diagnosis and treatment in low-resource settings. Each project consists of an adaptation phase (2 years: $500k total costs/year) and validation phase (3 years: $1M total costs/year). Projects are selected through NIH peer review process by a carefully-selected special emphasis panel briefed on the goals of the program. Projects are competitively vetted for Phase II funding based on completion of Phase I milestones. The program currently supports seven technologies for cancer detection, diagnosis and treatment, each of which is progressing towards experimental and clinical validation. The first project is an LED-based photodynamic therapy device for oral cancer, that has similar efficacy in vivo and ex vivo as existing laser phototherapy. Another supported project is an automated high resolution microendoscope for cervical cancer detection, with an impressive histological concordance in detecting CIN2/3 (90%+ for CIN3). Two cervical cancer cryotherapy projects are funded: a cryopen, that can achieve an approximately 4.0 mm depth of necrosis (>90% of disease) for cervical cancer treatment, and an efficient cryopop device that consumes less than 10% of CO2, compared to commercially-available devices and exhibits comparable therapeutic efficacy in ballistic gel studies. The program is also supporting two POC tests, a HPV test and a Hepatitis C viral antigen level and viral load detection. Additionally, a breast cancer triaging device/algorithm, with 95% sensitivity and capabilities to reduce false positive detection rate by 40%, is also being supported. Each project has its own detailed outline for Phase I and Phase II studies, which will be highlighting in our presentation. The program is in the process of adding another six projects, and it is anticipated that by year seven of the program, at least nine projects will have progressed through optimization, clinical validation, and business planning for commercialization and field/clinic dissemination. Through these process, we will uniquely accelerate these technologies for success in clinical translation. Citation Format: Michael Gwede, Paul Pearlman, Pushpa Tandon, Miguel Ossandon, Lokesh Agrawal, Houston Baker, Vinay Pai, Tiffani Lash. The program for cancer detection, diagnosis, and treatment technologies for global health: Translating affordable, minimally invasive point-of-care technologies to less-resourced settings. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1428.

Abstract 9 Cancer kills more people worldwide than HIV/AIDS, tuberculosis, and malaria combined, and low- and middle-income countries (LMICs) bear the majority of this burden. While success in detection, diagnosis, and treatment has been reported in LMICs through the use of low-cost, point-of-care (POC) technologies, this area has been largely overlooked by the medical device industry and venture capital communities, as low-cost solutions offer less financial incentive for investment. The program presented here aims to simplify the pathway to market by funding investigation teams to adapt and validate existing technologies in low-resource settings. This program specifically supports the translation of these technologies, prioritizing patient outcomes in a manner not typically seen. This program, currently in its second year, will soon support 15 technologies for cancer detection, diagnosis, and treatment (e.g., in vitro assays, imaging devices, ablation devices). It is anticipated that by year seven of the program, at least nine projects will have progressed through optimization, clinical validation, and business planning for dissemination and commercialization. Each project consists of an adaptation phase (two years: $500k total costs/year) and validation phase (three years: $1M total costs/year). Projects are selected through the National Institutes of Health peer review process by a special emphasis panel briefed on the goals of the program. Projects are competitively vetted for Phase II funding based on completion of Phase I milestones. All teams contain expertise in engineering, oncology, and business/manufacturing, uniquely leveraging their devices for success in translation. The seven preliminarily funded projects are making strides in optimization, and the projects range from an LED-based photodynamic therapy device for oral cancer to POC tests for Hepatitis C viral antigen level and viral load detection. This program is funded by the National Cancer Institute and the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors.